4//SEC Filing
Easom Eric 4
Accession 0001610717-24-000013
CIK 0001880438other
Filed
Jan 3, 7:00 PM ET
Accepted
Jan 4, 6:05 PM ET
Size
27.1 KB
Accession
0001610717-24-000013
Insider Transaction Report
Form 4
Easom Eric
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
2024-01-02$20.09/sh−2,777$55,802→ 2,130 total
Holdings
- 97,058(indirect: See Footnote)
Common Stock
- 1,015,766(indirect: See Footnote)
Common Stock
- 97,058(indirect: See Footnote)
Common Stock
Footnotes (4)
- [F1]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2023.
- [F2]Consists of shares of Common Stock held by the Easom Living Trust dated August 21, 2019.
- [F3]Consists of shares of Common Stock held by the C Easom Irrevocable Trust dated October 8, 2021.
- [F4]Consists of shares of Common Stock held by the Jude Easom Irrevocable Trust dated October 8, 2021.
Documents
Issuer
AN2 Therapeutics, Inc.
CIK 0001880438
Entity typeother
Related Parties
1- filerCIK 0001914503
Filing Metadata
- Form type
- 4
- Filed
- Jan 3, 7:00 PM ET
- Accepted
- Jan 4, 6:05 PM ET
- Size
- 27.1 KB